Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs

Journal of the American Veterinary Medical Association

Volumn 224, Issue 3, 2004, Pages 388-394

  Boria, Pedro A ^a   Murry, Daryl J ^c   Bennett, Peter F ^d   Glickman, Nita W ^a   Snyder, Paul W ^a   Merkel, Brenna L ^b   Schlittler, Deborah L ^a   Mutsaers, Anthony J ^a   Thomas, Rose M ^a   Knapp, Deborah W ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Melbourne Veterinary Referral Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; CISPLATIN; PIROXICAM;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; DOG; DRUG CLEARANCE; MAXIMUM TOLERATED DOSE; MELANOMA; MOUTH TUMOR; NEPHROTOXICITY; NONHUMAN; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG INTERACTIONS; FEMALE; MALE; MELANOMA; MOUTH NEOPLASMS; PIROXICAM; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 9144244174     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2004.224.388     Document Type: Article

References (25)

1. Withrow S. Cancer of the oral cavity. In: Withrow S, MacEwen E, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;305-317.
2. Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783-1786.
3. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001;218:1444-1448.
4. Kitchell BE, Brown DM, Luck EE, et al. Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 1994;204:229-236.
5. Knapp DW, Richardson RC, Bonney PL, et al. Cisplatin therapy in 41 dogs with malignant tumors. J Vet Intern Med 1988;2:41-46.
6. Brooks MB, Matus RE, Leifer CE, et al. Chemotherapy versus chemotherapy plus radiotherapy in the treatment of tonsillar squamous cell carcinoma in the dog. J Vet Intern Med 1988;2:206-211.
7. Ogilvie GK, Obradovich JE, Elmslie RE, et al. Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc 1991;198:1618-1621.
8. Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:1580-1583.
9. Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.
10. Walker EM Jr, Walker SM. Evolution of chemotherapy with platinum compounds. Ann Clin Lab Sci 1999;29:263-274.
11. Klein J, Bentur Y, Cheung D, et al. Renal handling of cisplatin: interactions with organic anions and cations in the dog. Clin Invest Med 1991;14:388-394.
12. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.
13. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221-226.
14. Owens L. TNM classification of tumors in domestic animals. World Health Organization Bulletin. Geneva: 1980;23.
15. Ogilvie GK, Krawiec DR, Gelberg HB, et al. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. Am J Vet Res 1988;49:1076-1078.
16. Moore AS, Rand WM, Berg J, et al. Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs. J Am Vet Med Assoc 1994;205:441-443.
17. SAS procedures guide: version 8 edition. Cary, NC: SAS Institute Inc, 1999;449-601.
18. SAS/STAT user's guide: version 8 edition. Cary, NC: SAS Institute Inc, 1999;1797-1852, 2505-2552, 2569-2658.
19. Buhles WC Jr, Theilen GH. Preliminary evaluation of Neomycin in feline and canine squamous cell carcinoma. Am J Vet Res 1973;34:289-291.
20. Pinzani V, Bressolle F, Hang J, et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994;35:1-9.
21. Evans EE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989;16:327-336.
22. Pestili de Almeida EM, Piche C, Sirois J, et al. Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001;49:867-875.
23. Mohammed SI, Khan KNM, Sellers RS, et al. Expression of cyclo-oxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2004;in press.
24. Mohammed SI, Coffman K, Glickman NW, et al. Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2001;64:1-4.
25. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and independent pathways in cisplatin-resistant and sensitive human ovarian cancer. Cancer Res 1999;59:3077-3083.